Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study

Authors: Pablo Conesa-Zamora, Javier Ruiz-Cosano, Daniel Torres-Moreno, Ignacio Español, María D Gutiérrez-Meca, Javier Trujillo-Santos, Elena Pérez-Ceballos, Rocío González-Conejero, Javier Corral, Vicente Vicente, Miguel Pérez-Guillermo

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

The interplay between genetic susceptibility and carcinogenic exposure is important in the development of haematopoietic malignancies. EPHX1, NQO1 and PON1 are three genes encoding proteins directly involved in the detoxification of potential carcinogens.

Methods

We have studied the prevalence of three functional polymorphisms affecting these genes rs1051740 EPHX1, rs1800566 NQO1 and rs662 PON1 in 215 patients with lymphoma and 214 healthy controls.

Results

Genotype frequencies for EPHX and NQO1 polymorphisms did not show any correlation with disease. In contrast, the GG genotype in the PON1 polymorphism was found to be strongly associated with the disease (15.3% vs. 4.7%; OR = 3.7 CI (95%): 1.8-7.7; p < 0.001). According to the pathological diagnosis this association was related to follicular (p = 0.004) and diffuse large B-cell (p = 0.016) lymphomas.

Conclusions

Despite the fact that further confirmation is needed, this study shows that the PON1 GG genotype in rs662 polymorphism could be a risk factor for B-cell lymphomas.
Appendix
Available only for authorised users
Literature
1.
Shimada T: Xenobiotic-Metabolizing Enzymes involved in Activation and Detoxification of Carcinogenic Polycyclic Aromatic Hydrocarbons. Drug Metab Pharmacokinet. 2006, 21: 257-276. 10.2133/dmpk.21.257.CrossRefPubMed
2.
Rose RL, Hodgson E: Adaptation to Toxicants. Chemical and Environmental Factors Affecting Metabolism of Xenobiotics. Introduction to biochemical toxicology. Edited by: Hodgson E, Smart RC. 2001, New York: Willey, 163-198.
3.
Fritschi L, Benke G, Hughes AM: Occupational Exposure to Pesticides and Risk of Non-Hodgkin’s Lymphoma. Am J Epidemiol. 2005, 162: 849-857. 10.1093/aje/kwi292.CrossRefPubMed
4.
Roulland S, Lebailly P, Lecluse Y: Characterization of the t(14;18) BCL2-IGH translocation in farmers occupationally exposed to pesticides. Cancer Res. 2004, 64: 2264-2269. 10.1158/0008-5472.CAN-03-3604.CrossRefPubMed
5.
Wong O, Fue H: Exposure to benzene and non-Hodgkin lymphoma, an epidemiologic overview and an ongoing case–control study in Shanghai. Chem Biol Interact. 2005, 153–154: 33-41.CrossRefPubMed
6.
Fritschi L, Benke G, Hughes AM: Risk of non-Hodgkin lymphoma associated with occupational exposure to solvents, metals, organic dusts and PCBs (Australia). Cancer Causes Control. 2005, 16: 599-607. 10.1007/s10552-004-7845-0.CrossRefPubMed
7.
Lamm SH, Engel A, Byrd DM: Non-Hodgkin lymphoma and benzene exposure: a systematic literature review. Chem Biol Interact. 2005, 153–154: 231-237.CrossRefPubMed
8.
De Roos AJ, Gold LS, Wang S: Metabolic gene variants and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1647-1653. 10.1158/1055-9965.EPI-06-0193.CrossRefPubMed
9.
Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A: Association between xenobiotic gene polymorphisms and non-Hodgkin’s lymphoma risk. Br J Haematol. 2002, 118: 477-481. 10.1046/j.1365-2141.2002.03606.x.CrossRefPubMed
10.
Sarmanova J, Benesova K, Gut I, Nedelcheva-Kristensen V, Tynkova L, Soucek P: Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin’s and non-Hodgkin’s lymphomas. Hum Molec Genet. 2001, 10: 1265-1273. 10.1093/hmg/10.12.1265.CrossRefPubMed
11.
Barry KH, Zhang Y, Lan Q: Genetic variation in metabolic genes, occupational solvent exposure, and risk of non-hodgkin lymphoma. Am J Epidemiol. 2011, 173: 404-413. 10.1093/aje/kwq360.CrossRefPubMedPubMedCentral
12.
Infante-Rivard C, Vermunt JK, Weinberg CR: Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in families of children with acute lymphoblastic leukemia. Am J Epidemiol. 2007, 165: 1248-1254. 10.1093/aje/kwm022.CrossRefPubMedPubMedCentral
13.
Infante-Rivard C, Labuda D, Krajinovic M, Sinnett D: Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms. Epidemiology. 1999, 10: 481-487. 10.1097/00001648-199909000-00004.CrossRefPubMed
14.
Swerdlow SH, Campo E, Harris NL: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008, Lyon, France: IARC Press
15.
Ruiz-Cosano J, Conesa-Zamora P, González-Conejero R: Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: influence of geographical factors and occupational exposure. Mol Carcinog. 2012, 51: 508-513. 10.1002/mc.20814.CrossRefPubMed
16.
17.
Cirera L, Rodríguez M, Giménez J: Effects of public health interventions on industrial emissions and ambient air in Cartagena, Spain. Environ Sci Pollut Res Int. 2009, 16: 152-161. 10.1007/s11356-008-0091-3.CrossRefPubMed
18.
Real D: 1197/1979 de 20 de Febrero, por el que se declara aplicable a parte del término municipal de Cartagena (Murcia) las medidas y beneficios previstos en la Ley 38/1972 de Diciembre, y Reglamentación complementaria de protección del ambiente atmosférico]. Spanish Government Official Bulletin (BOE). 1979, 123: 11406-
19.
López-Abente G, Hernández-Barrera V, Pollán M: Municipal pleural cancer mortality in Spain. Occup Environ Med. 2005, 62: 195-199. 10.1136/oem.2004.015743.CrossRefPubMedPubMedCentral
20.
Lopez-Abente G, Aragones N, Ramis R: Municipal distribution of bladder cancer mortality in Spain: possible role of mining and industry. BMC Public Health. 2006, 6: 17-10.1186/1471-2458-6-17.CrossRefPubMedPubMedCentral
21.
22.
Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y: A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://​analysis.​bio-x.​cn). Cell Res. 2009, 19: 519-523. 10.1038/cr.2009.33.
23.
Hassett C, Aicher L, Sidhu JS, Omiecinski CJ: Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Molec Genet. 1994, 3: 421-428. 10.1093/hmg/3.3.421.CrossRefPubMedPubMedCentral
24.
Tumer TB, Sahin G, Arinç E: Association between polymorphisms of EPHX1 and XRCC1 genes and the risk of childhood acute lymphoblastic leukemia. Arch Toxicol. 2012, 86: 431-439. 10.1007/s00204-011-0760-8.CrossRefPubMed
25.
Silveira Vda S, Canalle R, Scrideli CA, Queiroz RG, Tone LG: Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children. Environ Mol Mutagen. 2010, 51: 48-56.PubMed
26.
Chauhan PS, Ihsan R, Mishra AK, Yadav DS, Saluja S, Mittal V: High order interactions of xenobiotic metabolizing genes and P53 codon 72 polymorphisms in acute leukemia. Environ Mol Mutagen. 2012, 53: 619-630. 10.1002/em.21723.CrossRefPubMed
27.
da Silva SV, Canalle R, Scrideli CA, Queiroz RG, Bettiol H, Valera ET: Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia. Leuk Res. 2009, 33: 898-901. 10.1016/j.leukres.2008.12.006.CrossRef
28.
Moran JL, Siegel D, Ross D: A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Nat Acad Sci. 1999, 96: 8150-8155. 10.1073/pnas.96.14.8150.CrossRefPubMedPubMedCentral
29.
Rothman N, Smith MT, Hayes RB: Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997, 57: 2839-2842.PubMed
30.
Chan JY, Ugrasena DG, Lum DW, Lu Y, Yeoh AE: Xenobiotic and folate pathway gene polymorphisms and risk of childhood acute lymphoblastic leukaemia in Javanese children. Hematol Oncol. 2011, 29: 116-123. 10.1002/hon.965.CrossRefPubMed
31.
Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D: Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer. 2002, 97: 230-236. 10.1002/ijc.1589.CrossRefPubMed
32.
Stanulla M, Dynybil C, Bartels DB, Dördelmann M, Löning L, Claviez A: The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group. Haematologica. 2007, 92: 1581-1582. 10.3324/haematol.10260.CrossRefPubMed
33.
Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA: NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol. 2008, 168: 1221-1232.CrossRefPubMedPubMedCentral
34.
Eguchi-Ishimae M, Eguchi M, Ishii E, Knight D, Sadakane Y, Isoyama K: The association of a distinctive allele of NAD(P)H:quinine oxidoreductase with pediatric acute lymphoblastic leukemias with MLL fusion genes in Japan. Haematologica. 2005, 90: 1511-1515.PubMed
35.
Sirma S, Agaoglu L, Yildiz I, Cayli D, Horgusluoglu E, Anak S: NAD(P)H:quinine oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia. Pediatr Blood Cancer. 2004, 43: 568-570. 10.1002/pbc.20098.CrossRefPubMed
36.
Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005, 46: 1239-1247. 10.1194/jlr.M400511-JLR200.CrossRefPubMed
37.
Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet. 1993, 3: 73-76. 10.1038/ng0193-73.CrossRefPubMed
38.
Kokouva M, Koureas M, Dardiotis E, Almpanidou P, Kalogeraki A, Kyriakou D: Relationship between the paraoxonase 1 (PON1) M55L and Q192R polymorphisms and lymphohaematopoietic cancers in a Greek agricultural population. Toxicology. 2012, in press
39.
Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, Rothman N: Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010, 42: 661-4. 10.1038/ng.626.CrossRefPubMedPubMedCentral
40.
Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H: GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. 2011, 7: e1001378-10.1371/journal.pgen.1001378.CrossRefPubMedPubMedCentral
41.
Skibola CF, Bracci PM, Halperin E, Conde L, Craig DW, Agana L: Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. 2009, 41: 873-5. 10.1038/ng.419.CrossRefPubMedPubMedCentral
42.
Vijai J, Kirchhoff T, Schrader KA, Brown J, Dutra-Clarke AV, Manschreck C: Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet. 2013, 9: e1003220-10.1371/journal.pgen.1003220.CrossRefPubMedPubMedCentral
Metadata
Title
Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study
Authors
Pablo Conesa-Zamora
Javier Ruiz-Cosano
Daniel Torres-Moreno
Ignacio Español
María D Gutiérrez-Meca
Javier Trujillo-Santos
Elena Pérez-Ceballos
Rocío González-Conejero
Javier Corral
Vicente Vicente
Miguel Pérez-Guillermo
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-228

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells

Research article

Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes

Research article

Radiation mitigating properties of the lignan component in flaxseed

Research article

The roles of Notch1 expression in the migration of intrahepatic cholangiocarcinoma

Research article

Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer

Research article

Patient side cost and its predictors for cervical cancer in Ethiopia: a cross sectional hospital based study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits